FindTrial
Sign In

LC28-0126

DRUG2 trials

Sponsors

LG Life Sciences, LG Chem

Conditions

Healthy

Phase 1

Study to Investigate the Safety and Pharmacokinetic Characteristics of LC28-0126 in Healthy Male Subjects
CompletedNCT01737424
LG Life SciencesHealthy
Start: 2012-12-31End: 2013-09-30Updated: 2014-03-14
A Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of LC28-0126.
CompletedNCT03196804
LG ChemHealthy
Start: 2017-06-07End: 2017-11-15Updated: 2018-04-11

Related Papers

Pharmacokinetics and Tolerability of LC28-0126, a Novel Necrosis Inhibitor, After Multiple Ascending Doses: A Phase I Randomized, Double-blind, Placebo-controlled Study in Healthy Male Subjects.
2020-09-244 citations
Abstract 263: Therapeutic Potential of a Novel Necrosis Inhibitor in Myocardial Ischemia-reperfusion Injury
Circulation Research2015-07-171 citations